Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide. The company s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. It offers ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company also engages in developing AZ-002 (Staccato alprazolam) for treating patients with acute repetitive seizures, as well as in Phase 2a study for patients with epilepsy; and AZ-007 (Staccato zaleplon) for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. It has collaboration agreement with Grupo Ferrer Internacional S.A. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ALXA